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Objective: Estradiol (E2)-based hormonal contraceptives impact less than ethinylstradiol (EE) 
contraceptives on venous thromboembolism (VTE) in comparison to formulations with EE.
Study design: In this article, the pharamacologic data of EE and E2 were briefly reviewed, 
along with the induced biologic effect. These data were then related to a recent large international 
prospective, controlled, non-interventional cohort active surveillance study, on the cardiovascular 
risk of users of different types of combined estro-progestin contraceptive (CEPC).
Results: The crude HR for E2-valerate (E2V)/dienogest vs other CEPCs with EE was 0.8 (95% 
CI, 0.4–1.6), but when the data were corrected for age, body mass index, duration of use, and 
family history of VTE, the corresponding adjusted HR was 0.5 (95% CI, 0.2–1.0). A compari-
son of the E2V/dienogest and EE/levonorgestrel groups showed that the two contraceptives 
induced a similar VTE risk with the crude and adjusted VTE HRs of 0.7 (95% CI, 0.3–1.8) and 
0.5 (95% CI, 0.2–1.3), respectively. Similar results were obtained when the observation was 
prolonged to January 2017.
Conclusions: The reduced impact of E2 vs EE on coagulation translates into the epidemio-
logic evidence of a reduced number of events in E2V vs EE users, when progestins other than 
levonorgestrel are used. However, E2 may continue to negatively impact on the risk of VTE, and 
this should not be forgotten at the time of prescription. Family history of VTE or thrombophilia, 
age, and obesity are risk factors for VTE too. If these risk factors are not taken into consideration 
and excluded, they can overcome or hide the higher safety of E2 vs CEPCs with EE.
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Introduction
Venous thromboembolism (VTE) is rare among healthy women of reproductive age 
showing an incidence of 1–5 events per 10,000 women-years.1
The possible increase of venous thromboembolism causes concerns in oral con-
traceptives users and medical people too.
Oral and nonoral estro-progestin combined contraceptives (CEPC) increase the 
risk of VTE, including deep venous thromboembolism and pulmonary embolism 
(PE).2,3 The risk is low (less than 5–12 events per 10,000 women-years of exposure) 
and lower than the VTE risk observed during pregnancy and in the postpartum 
period.4,5 Nevertheless, the possible increase of VTE during CEPCs causes concern 
in the scientific community, physicians, and users of hormonal contraceptives. The 
risk of venous thromboembolism is dependent on the effect of estrogens on coagu-
lation. Two different estrogens are nowadays used in CEPCs: estradiol (E2) (either 
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 micronized or valerate) and ethynylestradiol (EE). For many 
years EE has been the only estrogen present in CEPCs 
because it is more potent and has a better oral bioavailability 
(38%–48%) than other estrogens.6 When administered, EE 
increases procoagulatory factors and decreases anticoagu-
latory mechanisms,7,8 inducing a dose-related increase of 
VTE.9–11 Introduction in the market of low-dose CEPCs 
(containing <50 µg or less EE) led to a reduced risk of 
VTE,12,13 which, however, remained consistent even with 
very low EE doses (20 µg) or with the use of non-oral routes 
of administration (transdermal or vaginal).14
In the mid-1990s, several studies indicated that low-
dose CEPCs containing a combination of 30 µg EE and 150 
µg desogestrel had a risk of VTE higher than those con-
taining 30 µg EE and 150 µg levonorgestrel.12,15–17 Because 
desogestrel per se, administered as progestin-only contra-
ceptive, does not show any procoagulant effect and does 
not increase the risk of VTE,18 the reported increased VTE 
risk of EE-desogestrel vs EE-levonorgestrel can only be 
attributed to a different modulation of the procoagulatory 
effect of EE, exerted by the two progestins. Indeed, proges-
tins may counteract the procoagulant effects of estrogen to 
varying degrees. In fact, many studies indicated that some 
progestogens, particularly those with a high androgenic 
potency, antagonize more than others the risk of VTE 
associated with EE.12,15–17 Accordingly, the risk of VTE of 
the general population increases  two- to threefold in users 
of CEPCs containing EE associated with norethisterone, 
levonorgestrel, or norgestimate,2,9 and of sixfold in users 
of CEPCs containing desogestrel, gestodene, drospirenone, 
or cyproterone acetate.2,9,12,15–17
Menstrual irregularities reduce acceptance of CEPCs with 
doses of EE below 15 µg,19 but yet procoagulant effects of 
EE are reported also with doses of 10 µg. Accordingly, it is 
unlikely that the risk on VTE can be overcome by reducing 
the doses of EE contained in CPECs.
In 2009, CPECs containing E2 in the place of EE were 
marketed.
Methods
In this article, the possible advantages of using E2-based 
CPECs, in particular on VTE, were briefly reviewed. Briefly, 
the pharmacologic data on E2 and EE were reviewed and 
presented in conjunction with the biologic effect. This 
evaluation was preliminary to interpret new epidemiologic 
evidence on the cardiovascular risk associated with E2- vs 
EE-based CPECs.
Results
E2 versus EE: pharmacologic effects
Exogenously administered E2 is chemically identical 
to endogenous 17β-estradiol, the most potent natural 
estrogen produced by the ovary. Because of its low oral 
bioavailability (5%),20 the place of E2 in CPECs was 
taken by EE whose oral bioavailability was 38%–48%.21 
Micronization and esterification enhanced oral bioavail-
ability of E2,22 allowing its use in contraception. E2-val-
erate (E2V), the valerate ester of E2, is rapidly converted 
to E2 in the gut and liver,23 and it has a pharmacokinetic 
profile similar to E2. E2 is converted to estrone by the 
activity of 11 beta-hydroxylase. Because estrone can 
be reconverted, it represents a circulating reservoir for 
E2, allowing fairly stable E2 levels following oral E2V 
administration.24
E2 versus EE: biologic effects
E2 impacts less than EE on metabolic and hepatic param-
eters as documented by its neutral effect on lipids and its 
blunted effect on hepatic proteins, such as sex hormone-
binding globulin and angiotensinogen.25 A consequence of 
this reduced effect is its neutrality on blood pressure that 
instead is increased by EE-based CEPCs.26,27 In spite of the 
fact that CEPCs with E2 are marketed with non-androgenic 
progestins, their effect on various hemostatic parameters 
is similar or lower than that induced by CEPCs containing 
androgenic progestins (levonorgestrel) associated with EE, 
and lower than that exerted by the association of EE and 
nonandrogenic progestins.28–32
These reassuring results on the coagulatory mechanisms 
were recently confirmed by epidemiologic evidence.
E2 versus EE: epidemiologic evidence
The INAS-SCORE, a large international prospective, con-
trolled, noninterventional cohort active surveillance study, 
investigated the occurrence of VTE and other cardiovascular 
events over a 3- to 5-year period in E2V/dienogest and other 
EE-containing CEPC users. The study started to recruit in 
2009 up to 2012. First analysis was published in 2016.33 The 
last follow-up study was performed in 2017, and the results 
recently adjourned.34 The first results of the INAS score study 
that were published in 2016 were based on 50,203 new CEPC 
users followed up for to 5.5 years (mean value, 2.1 years).33 
Overall, 20.3% of these women had used E2V/dienogest, and 
79.7% other CEPCs (including 11.5% EE/levonorgestrel). 
Seventy-seven VTE were documented, of which only 1/3 
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with a severe clinical manifestation, such as PE (26 out of 
77 VTE cases; 34%).
The rate of VTE during E2V/dienogest (7.2 VTE per 
10,000 women-years [WY]), oral CEPCs (9.1 VTE per 10,000 
WY), and EE with levonorgestrel (9.9 VTE per 10,000 WY) 
was higher than in “no use” group (3.5 VTE per 10,000 WY).
The crude HR for E2V/dienogest vs other CEPCs was 0.8 
(95% CI, 0.4–1.6), but it became significant when the data 
were corrected for age, body mass index (BMI), duration of 
use, and family history of VTE (adjusted HR was 0.5 [95% 
CI, 0.2–1.0]). Vice versa, the risk of VTE was similar in users 
of E2V/dienogest and EE/levonorgestrel with a crude HR 
of 0.7 (95% CI, 0.3–1.8) and an adjusted HR of 0.5 (95% 
CI, 0.2–1.3).
Low adherence in the USA users prompted to a sub-
analysis of the INAS-SCORE performed only in the Euro-
pean countries with a prolongation of the observation.33 In 
this subanalysis, results did not change. The crude HR of 
VTE for E2V/dienogest vs other CEPCs was 0.9 (95% CI, 
0.4–1.8), but it became significant (adjusted HR of 0.4 with 
an upper 95% confidence limit of 0.98) when corrected for 
confoundings. The comparison of the E2V/dienogest and EE/
levonorgestrel confirmed the same risk of VTE between the 
two, with a crude and adjusted HR for VTE of 0.8 (95% CI, 
0.3–2.4) and 0.5 (95% CI, 0.2–1.5), respectively.
The extension phase was performed with the last patient at 
follow-up finalized in January 2017.34 At the end, 69,888 WY 
CEPCs exposure was analyzed. Data were limited to those 
obtained in Europe only. The VTE incidence was 7.1/10,000 
WY for EV/dienogest and 8.8/10,000 WY, for other CEPCs 
including pills with EE/levonorgestrel. The crude HRs for 
EV/dienogest vs other CEPCs and EE/levonorgestrel pills 
were 0.9 and 0.8 but the difference did not reach the sta-
tistical significance. When the data were corrected for age, 
BMI, duration of use, and family history, the HR for VTE of 
E2V/dienogest was significantly lower in comparison to all 
CEPCs (HR 0.4; 95% CI, 0.2–0.9), but not in comparison 
to EE/levonorgestrel pill.
Discussion
Given the popularity and widespread use of CEPCs, 
any increase in the relative risk of VTE associated with 
a particular CEPC formulation could translate into an 
important increase in absolute numbers. Nevertheless, the 
risk, which may be substantial (up to sixfold), multiplies a 
baseline risk that in the case of fertile women, particularly 
in young age, is very low. In the worst of the scenarios, it 
is assumed that the use of CPECs can cause an increase 
of about 1–1.2 VTE over 1000 exposed women per year. 
As the consequence, the documented clinical variances 
among the different CPECs formulations should be con-
fronted with the possibility to increase of 0.5 or 1.0 VTE 
over 1000 women per year. Clinicians, whose main focus 
is to increase the risk of not more than 0.5 VTE per 1000 
women year, were left with only one option, the associa-
tion of EE and a strong androgenic progestin. Those more 
concerned of individualization used also other CEPCs, 
taking the risk of increasing VTE rate of 1.0/1000 women 
per year. Nowadays, epidemiologic evidence supported by 
biochemical and pharmacologic data indicates that EE and 
androgenic progestins are not the only option for minimiz-
ing the risk of VTE associated with CEPCs use, but that 
E2V/dienogest is as safe as EE/levonorgestrel.33,35 Risk 
factors such as age, obesity, cigarette smoking, genetic 
predisposition, or familiar history of VTE may contribute 
to increase the risk of VTE,36 and to the final risk of VTE 
during CEPC use. In the INAS-SCORE, it was possible to 
correct for some of these confoundings, ultimately reveal-
ing a lower risk of VTE associated to E2V/dienogest than 
other CEPCs. These data stimulate two considerations: 
E2V/dienogest was already perceived by physicians and 
women as safer than other CEPCs, and accordingly, it was 
prescribed and used by women with a higher risk of VTE; 
E2V/dienogest was indeed safer than most other CEPCs, 
because when the data were corrected for known risk 
factors for VTE, it was associated with a lower VTE risk. 
Nevertheless, CEPCs containing E2 continue to negatively 
impact on coagulation. This should not be forgotten at the 
time of prescription. In the women with VTE risk factors, 
E2-based CEPCs do not represent a valid alternative to 
progestin-only contraceptives.36
Conclusion
In the case of E2-based CEPCs, the pharmacologic data and 
the modifications of surrogate markers correspond to the 
epidemiologic evidence. The reduced impact of E2 vs EE 
on coagulation translates into the epidemiologic evidence 
of a reduced number of events in E2V vs EE users, when 
progestins other than levonorgestrel are used. Accordingly, 
CEPCs with E2 may significantly reduce the overall VTE 
burden linked to the use of contraception and be used in 
place of EE/levonorgestrel. Indications to using an E2 can 
be various. Among these an eye should be directed to the 
preliminary data showing a tendency of a reduced risk of arte-
rial thromboembolism in E2V/dienogest vs EE/levonorgestrel 
users (HR 0.1; 95% CI, 0.0–1.2).33 The lack of attention at 





the time of prescription to risk factors may hide the higher 
safety of E2-based CEPCs.
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